Auspherix Limited （UK）

Auspherix is an anti-infective drug company dedicated to the discovery and development of a new class of organometallic antibiotics for severe, difficult-to-treat, or potentially life-threatening infections. Its new class of antibiotics demonstrates potent and broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including many multidrug-resistant (MDR) Gram-negative strains, addressing unmet global medical needs with significant market potential. The company is leveraging its proprietary organometallic chemistry platform to build a pipeline of novel antimicrobial agents, with an initial focus on treating complicated urinary tract infections (cUTI). Auspherix’s pipeline includes three structurally distinct small-molecule lead series, currently in preclinical development. As a private company, Auspherix is backed by experienced investors, including Australia’s Medical Research Commercialisation Fund (MRCF) and the UK’s Touchstone Innovations plc (AIM: IVO). The company is located at the Stevenage Bioscience Catalyst facility in the UK, a world-leading open innovation hub and center for rapidly growing biotech, pharmaceutical, and medtech businesses.